Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Eosinophilic Asthma Market During the Forecast Period, and Why?

In recent times, the eosinophilic asthma market has experienced swift expansion. Projections indicate that its value will rise from $2.69 billion in 2024 to $3.17 billion in 2025, marking a compound annual growth rate (CAGR) of 17.7%. This significant growth during the historic period can be credited to factors like heightened pollution, compromised immunity among the general population, increased incidences of eosinophilic asthma and prevalence of allergens and respiratory conditions, growth in healthcare spending, and a surge in R&D endeavors.

The market for eosinophilic asthma is predicted to experience substantial growth in the forthcoming years, ballooning to $6.01 billion by 2029 with a compound annual growth rate (CAGR) of 17.4%. The surge in the forecast period can be linked to the escalating incidence of respiratory illnesses, increased recognition and diagnostic rates, a broader range of therapeutic indications for monoclonal antibodies, heightened spending in healthcare infrastructure, and an uptick in personalised medical practices. The forecast period will be characterised by outstanding trends like the creation of targeted biologics, enhanced diagnostic instruments, customised treatment strategies, advanced drug delivery systems, incorporation of cyber health innovations, and broadened clinical trials for ground-breaking therapies.

What External and Internal Drivers Are Contributing to the Growth of the Eosinophilic Asthma Market’s Growth?

The escalating trend of smoking practices is anticipated to drive the expansion of the eosinophilic asthma market. These practices entail habitual or standard usage of tobacco products, dictated by the frequency, scenario, and length of smoking, often shaped by psychological, societal, and environmental aspects. The surge in smoking practices is attributed to elements like heightened stress levels, strategic advertising by tobacco corporations, lack of knowledge about potential health hazards, and the social normalization of smoking in certain communities. Treatment for eosinophilic asthma helps to lessen inflammation of the airways and enhance lung function, thereby aiding in smoking cessation by addressing the respiratory complications that primarily prompt individuals to persist with smoking. For instance, the National Health Service, a state department based in the UK, reported in December 2023 that there were approximately 408,700 hospital admissions owing to smoking in the 2022-23 timeframe, up from 389,800 in 2021-22, implying a growth of 4.8%. Hence, the increase in smoking rates propels the eosinophilic asthma market.

Get Your Free Sample of the Global Eosinophilic Asthma Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

Which Companies Are Poised to Shape the Future of the Eosinophilic Asthma Market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

What Are the Latest Innovations and Trends Influencing the Eosinophilic Asthma Market?

Dominant businesses in the eosinophilic asthma market are focusing on the development of cutting-edge medications that target specific immune pathways. These drugs aim to decrease inflammation and enhance patient outcomes through individualized treatment plans. One type of these lab-created molecules is a monoclonal antibody, which emulates the immune system’s ability to combat harmful pathogens such as viruses and bacteria. The production of these antibodies involves the fusion of a specific antibody-producing cell with a cancer cell, leading to the creation of vast quantities of identical antibodies. As an example, in August 2024, AstraZeneca plc, a biopharmaceutical firm based in the UK, announced that Fasenra was approved by the National Medical Products Association, a government agency in China, for the treatment of severe eosinophilic asthma. This condition is marked by high eosinophil levels, leading to inflammation and exacerbation of asthma symptoms. Fasenra, a monoclonal antibody, targets and diminishes eosinophils using a unique mechanism. It boosts the immune system by adhering to the IL-5 receptor on eosinophils, thereby reducing eosinophil levels within the blood and tissues. The dosage schedule requires an initial loading phase, followed by maintenance doses. Typically, patients receive injections every four weeks for the initial three doses, followed by every eight weeks after.

Get Instant Access to the Global Eosinophilic Asthma Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Industry Segments Are Leading the Development and Expansion of the Eosinophilic Asthma Market?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

What Regions Are Contributing Significantly to the Growth of the Eosinophilic Asthma Market?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Eosinophilic Asthma Market Defined?

Eosinophilic asthma is a form of asthma where high eosinophil counts, a specific white blood cell type, cause airway inflammation. This condition results in severe symptoms such as breathing issues and recurring flare-ups, with limited effectiveness from standard treatments such as inhaled steroids.

Browse Through More Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Breast Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-breast-cancer-treatment-global-market-report

Global Cell And Gene Therapy Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-gene-therapy-market-

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: